🔬 Introduction From Paul Ehrlich’s concept of the “magic bullet” in the early 20th century to the approval of the first ADC drug Mylotarg in 2000, antibody-drug conjugates (ADCs) have undergone a century of evolution and have become a “star therapy” in the field of precision oncology. This “biological missile,” which combines the targeting ability … Read more
Click the “blue WeChat name” below the title to quickly follow Source:Chinese Journal of Laboratory Medicine, 2025, 48(9): 1242-1247. Authors:Li Min, Yu Xiaochen, Guan Xiuru Abstract Drug resistance refers to the reduced or lost sensitivity of microorganisms to key drugs commonly used in clinical treatment. Bacteria can acquire resistance through various means. Bacterial resistance is … Read more
Click to follow Xiaobai Learning MedicineIntroduction: Since the approval of the first ADC drug Mylotarg® (Gemtuzumab Ozogamicin) in 2000, the number of ADC drugs has exploded, with 14 types of ADCs approved for market, and hundreds of ADC drugs undergoing clinical trials for various tumor indications. While ADCs are effective, their clinical development and application … Read more
Abstract National Natural Science Foundation Project Report HER2 exon 20 insertion mutations (HER2 20ins) are the most common type of HER2 mutations in lung cancer, accounting for 62%-90%. However, the response rate of these patients to existing targeted drugs (such as TKIs) is only 10%-30%, and the mechanisms of resistance have long been unclear. The … Read more
Antibody-Drug Conjugates (ADCs) are precision anti-cancer drugs that combine the targeting ability of antibodies with potent cytotoxic agents, achieving precise strikes against tumor cells through a “biological missile” design. As of July 2025, a total of 19 ADC drugs have been approved globally, widely used in the treatment of various cancers such as breast cancer … Read more
Currently, all marketed ADC drug molecules use a single small molecule toxin as the effective payload, but challenges such as drug resistance and limited therapeutic effects still exist. Therefore, clinical chemotherapy regimens often employ combinations of multiple drugs for combination therapy. Considering the clinical efficacy of combination chemotherapy, ADC drugs with two or more effective … Read more
ADC (Antibody-drug conjugate) is a new type of drug for cancer treatment. It is a complex formed by combining anti-tumor drugs with antibodies, allowing for precise delivery of the drug into tumor cells, thereby achieving targeted treatment of tumor cells. However, with the widespread application of ADCs, research has found that the issue of ADC … Read more
Antibody-drug conjugates (ADC) are formed by the coupling of specific targeting monoclonal antibodies and highly active cytotoxic drugs through linkers. With their unique pharmaceutical properties, ADC drugs exhibit strong anti-tumor activity in the field of cancer therapy, while also offering higher safety compared to traditional chemotherapy. In recent years, the development of ADC drugs in … Read more
*For reference only by medical professionals The latest review reports that ADC drug resistance is related to antigen expression, ADC processing, and payload efficacy. Antibody-drug conjugates (ADC) are formed by the conjugation of specific targeting monoclonal antibodies and highly active cytotoxic drugs via linkers. With their unique pharmacological properties, ADC drugs exhibit powerful anti-tumor activity … Read more
